~~<i id='D7C47C8CEB'><strike id='D7C47C8CEB'><tt id='D7C47C8CEB'><pre id='D7C47C8CEB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：knowledge 2025-10-02 21:06:49 - browse：9

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Solve the antibiotic resistance crisis with preventive drugs

focus

entertainment

explore

hotspot

BusinessmanVivekRamaswamyandformerU.N.AmbassadorNikkiHaleyAPPhoto/MorryGashTheyoungestcandidateonWed

WSS

STAT Summit: How a Chicago ER doctor tackles gun violence

2023 STAT Wunderkinds: get to know the winners

Roche's accidental data boosts hopes for anti

How the first Native Hawaiian psychiatrist helped diversify medicine

DeSantis wants to import drugs. Biden’s FDA blasted his plan

How climate

knowledge

fashion

focus

Walensky prepares to leave CDC — and Congress — behind

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

New air purifier tech could be key to improving indoor air quality

Impact of Dobbs ruling felt at reproductive medicine meeting

State Dept. review finds Biden bears some blame for Afghanistan failures

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Apple is now the first public company to be valued at $3 trillion

FDA advisory panel to debate high blood pressure devices

Virginia high school admissions case could be legal follow

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

focus

UnitedHealth’s board chair also owns a personal investment firm

Republicans love RFK Jr. What's that tell us about health in 2024?

FDA warns J&J's Abiomed: We will regulate your software

Pharmacists can make shortage drugs, but at what cost?

FDA gives detailed accounting of AI

How the drug

focus

entertainment

explore

hotspot